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An otherwise healthy girl aged 4 years was
observed because of a 6-month history of tachycar-
dia, polyphagia, chronic cough and agitation.
Physical examination revealed hiperhydrosis,
exuberant exophthalmia (figure 1) and a palpable,
elastic and painless goitre. Laboratory work up
showed an increased FT4, low thyroid-stimulating
hormone (TSH) and positive thyrotropin receptor
antibodies (TRABs) (figure 2), and thyroid ultrason-
ography demonstrated a diffusely heterogeneous,
enlarged gland with no nodules, compatible with
Graves’ disease. The girl was initiated immediately
to treatment with tiamazole (MTZ) and propran-
olol, and after few months, an euthyroid state was
achieved and maintained until 2 years (figure 2).
After this period, MTZ treatment was suspended
and 1 month later, she returned with restless sleep
and daytime agitation. Laboratory work up showed
a TSH<0.005 μU/mL, T4L of 0.98 ng/mL and a
positive TRABs and MTZ treatment (figure 2) was
reintroduced.
At 7 years, she presented with worsening exoph-
thalmia, eyelid retraction, lagophthalmos (figure 1)
Figure 1 Exophthalmia observed on physical
examination at diagnosis time (A). Exophthalmia, eyelid
retraction and lagoftalmos at 7 years (B). Actually: no
exophthalmia (C).
Figure 2 Longitudinal evaluation of thyroid function (FT4 and thyroid-stimulating hormone), thyrotropin receptor
antibodies levels and treatment performed from the diagnosis moment to present time.
Learning points
▸ A characteristic feature of Graves’ disease is
ophthalmopathy. In fact, its presence should
raise immediate suspicion of Graves’ disease.
Its cause remains uncertain, but a shared
antigen in the orbit and thyroid gland, such as
the thyrotropin receptor, seems to be a
probable cause.
▸ Ophthalmopathy treatment depends on the
phase and severity of the disease. The majority
of patients only require conservative measures,
although sometimes corticotherapy is needed.
▸ This case demonstrates a therapeutic challenge
of a paediatric case of Graves’ disease, where
the difficulties of assisting remission with
medical treatment, prompted to a definitive
treatment. In this case, surgery was preferred
because of the large thyroid tissue volume and
iodine131 risks of exacerbate ophthalmopathy.
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and a bigger goitre (left lobe 17×50×19 mm, right lobe
20×55×22 mm), with worsening of hyperthyroidism and
although MTZ dosage was adjusted (figure 2), the girl devel-
oped asymptomatic bilateral papilloedema. Orbit CT scan
showed compressive optic neuropathy and she was started
immediately on intravenous methylprednisolone with favourable
clinical response. Two months later, she was submitted to a total
thyroidectomy and was started on levothyroxine. One year later,
she remains well, without exophthalmos (figure 1).
Graves’ disease is a rare, but a leading cause of paediatric
hyperthyroidism.1 A typical finding is Graves’ ophthalmopathy,
often mild and self-limited, but in 3–5% of cases is associated
with risk of vision loss.2 3 The first-line treatment is synthetic
antithyroid but when remission is not achieved, definitive treat-
ment should be considered. The choice between surgery and
iodine131 is individualised, considering the patient and the
disease characteristics.1
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